[1. The mucopolysaccharidoses. The metabolic and molecular bases of inherited disease; [Internet]. 2001.]Search in Google Scholar
[2. D’Aco K, Underhill L, Rangachari L, Arn P, Cox GF, Giugliani R, et al. Diagnosis and treatment trends in mucopolysaccharidosis I: findings from the MPS I Registry. Eur J Pediatr. 2012;171(6):911-9.10.1007/s00431-011-1644-x]Search in Google Scholar
[3. Scott HS, Guo X-H, Hopwood JJ, Morris CP. Structure and sequence of the human α-L-iduronidase gene. Genomics. 1992;13(4):1311-3.10.1016/0888-7543(92)90053-U]Search in Google Scholar
[4. Taylor J, Gibson G, Brooks D, Hopwood J. α-l-Iduronidase in normal and mucopolysaccharidosis-type-I human skin fibroblasts. Bioch J. 1991;274 (Pt 1):263-8.10.1042/bj2740263]Search in Google Scholar
[5. Scott HS, Bunge S, Gal A, Clarke LA, Morris CP, Hop-wood JJ. Molecular genetics of mucopolysaccharidosis type I: diagnostic, clinical, and biological implications. Hum Mutat. 1995;6(4):288-302.10.1002/humu.1380060403]Search in Google Scholar
[6. Brooks D. The immunochemical analysis of enzyme from mucopolysaccharidoses patients. JIMD. 1993;16(1):3-15.10.1007/BF00711309]Search in Google Scholar
[7. Scott HS, Litjens T, Nelson PV, Brooks DA, Hopwood JJ, Morris CP. α-L-Iduronidase mutations (Q70X and P533R) associate with a severe Hurler phenotype. Hum Mutat. 1992;1(4):333-9.10.1002/humu.1380010412]Search in Google Scholar
[8. Bertola F, Filocamo M, Casati G, Mort M, Rosano C, Tylki-Szymanska A, et al. IDUA mutational profiling of a cohort of 102 European patients with mucopolysaccharidosis type I: identification and characterization of 35 novel α-L-iduronidase (IDUA) alleles. Hum Mutat. 2011;32(6):E2189-210.10.1002/humu.21479]Search in Google Scholar
[9. Clarke LA, Nelson PV, Warrington CL, Morris CP, Hopwood JJ, Scott HS. Mutation analysis of 19 North American mucopolysaccharidosis type I patients: identification of two additional frequent mutations. Hum Mutat. 1994;3(3):275-82.10.1002/humu.1380030316]Search in Google Scholar
[10. Jurca C, Bembea M, Pallag A, Muresan M, Szilagyi A, Balmos A, et al. Pharmacotherapeutical considerations in the treatment and management of neonatal hyperammonaemia. Farmacia. 2018;66(2):216-22.]Search in Google Scholar
[11. Patlas M, Hadas-Halpern I, Abrahamov A, Zimran A, Elstein D. Repeat abdominal ultrasound evaluation of 100 patients with type I Gaucher disease treated with enzyme replacement therapy for up to 7 years. Hematol J. 2002;3(1):17-20.10.1038/sj.thj.6200152]Search in Google Scholar
[12. Weinreb NJ, Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, et al. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med. 2002;113(2):112-9.10.1016/S0002-9343(02)01150-6]Search in Google Scholar
[13. Wang D, Shukla C, Liu X, Schoeb TR, Clarke LA, Bed-well DM, et al. Characterization of an MPS IH knock-in mouse that carries a nonsense mutation analogous to the human IDUA-W402X mutation. Mol Genet Metab. 2010;99(1):62-71.10.1016/j.ymgme.2009.08.002279504019751987]Search in Google Scholar
[14. Taghikhani M, Khatami S, Abdi M, Hakhamaneshi MS, Alaei MR, Zamanfar.D J. Mutation analysis and clinical characterization of Iranian patients with mucopolysaccharidosis type I. Clin Lab Anal. 2019;00:e2296310.1002/jcla.22963680531931386236]Search in Google Scholar
[15. Zahoor MY, Cheema HA, Ijaz S, Anjum MN, Ramzan K, Bhinder MA. Mapping of IDUA gene variants in Pakistani patients with mucopolysaccharidosis type 1. J Pediatr Endocrinol Metab. 2019;32(11):1221-1227.10.1515/jpem-2019-018831473686]Search in Google Scholar
[16. Clarke LA, Giugliani R, Guffon N, Jones SA, Keenan HA, Munoz-Rojas MV et al. Genotype-phenotype relationships in mucopolysaccharidosis type I (MPS I): Insights from the International MPS I Registry. Clin Genet. 2019;96(4):281-289.10.1111/cge.13583685215131194252]Search in Google Scholar
[17. Zanetti A, D’Avanzo F, Rigon L, Rampazzo A, Concolino D, Barone R, et al. Molecular diagnosis of patients affected by mucopolysaccharidosis: a multicenter study. Eur J Pediatr. 2019;178(5):739-753.10.1007/s00431-019-03341-8645979130809705]Search in Google Scholar
[18. Beesley CE, Meaney CA, Greenland G, Adams V, Vellodi A, Young EP, et al. Mutational analysis of 85 mucopolysaccharidosis type I families: frequency of known mutations, identification of 17 novel mutations and in vitro expression of missense mutations. Hum Genet. 2001;109(5):503-11.10.1007/s00439010060611735025]Search in Google Scholar
[19. Pollard LM, Jones JR, Wood TC. Molecular characterization of 355 mucopolysaccharidosis patients reveals 104 novel mutations. JIMD. 2013;36(2):179-87.10.1007/s10545-012-9533-722976768]Search in Google Scholar
[20. Bunge S, Kleijer WJ, Steglich C, Beck M, Zuther C, Morris CP, et al. Mucopolysaccharidosis type I: identification of 8 novel mutations and determination of the frequency of the two common α-L-iduronidase mutations (W402X and Q70X) among European patients. Hum Mol Genet. 1994;3(6):861-6.10.1093/hmg/3.6.8617951228]Search in Google Scholar
[21. Uttarilli A, Ranganath P, Matta D, Md Nurul Jain J, Prasad K, Babu AS, et al. Identification and characterization of 20 novel pathogenic variants in 60 unrelated Indian patients with mucopolysaccharidoses type I and type II. Clin Genet. 2016;90(6):496-508.10.1111/cge.1279527146977]Search in Google Scholar
[22. Terlato NJ, Cox GF. Can mucopolysaccharidosis type I disease severity be predicted based on a patient’s genotype? A comprehensive review of the literature. Genet Med. 2003;5(4):286-94.10.1097/01.GIM.0000078027.83236.4912865757]Search in Google Scholar
[23. Yogalingam G, Guo XH, Muller V, Brooks DA, Clements P, Kakkis E, et al. Identification and molecular characterization of α-L-iduronidase mutations present in mucopolysaccharidosis type I patients undergoing enzyme replacement therapy. Hum Mutat. 2004;24(3):199-207.10.1002/humu.20081]Search in Google Scholar
[24. Gatti R, DiNatale P, Villani G, Filocamo M, Muller V, Guo X-H, et al. Mutations among Italian mucopolysaccharidosis type I patients. Journal of inherited metabolic disease. 1997;20(6):803-6.10.1023/A:1005323918923]Search in Google Scholar
[25. Gort L, Chabás A, Coll MJ. Analysis of five mutations in 20 mucopolysaccharidosis type I patients: high prevalence of the W402X mutation. Hum Mutat. 1998;11(4):332-3.10.1002/(SICI)1098-1004(1998)11:4<332::AID-HUMU16>3.0.CO;2-P]Search in Google Scholar
[26. Matte U, Yogalingam G, Brooks D, Leistner S, Schwartz I, Lima L, et al. Identification and characterization of 13 new mutations in mucopolysaccharidosis type I patients. Mol Genet Metab. 2003;78(1):37-43.10.1016/S1096-7192(02)00200-7]Search in Google Scholar
[27. Li P, Wood T, Thompson JN. Diversity of mutations and distribution of single nucleotide polymorphic alleles in the human α-l-iduronidase (IDUA) gene. Genet Med. 2002;4(6):420.10.1097/00125817-200211000-00004]Search in Google Scholar